P494: A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK-MYELODYSPLASIA

• Anthony Selwyn Stein,
• Mojca Jongen-Lavrencic,
• Sylvain Garciaz,
• Gerwin A Huls,
• Abhishek Maiti,
• Nicolas Boissel,
• Stephane De Botton,
• Shaun Fleming,
• C. Michel Zwaan,
• David C. de Leeuw,
• Pinkal Desai,
• Martha Lucia Arellano,
• David Avigan,
• Saskia Langemeijer,
• Kyle Jensen,
• Timothy Wagenaar,
• Gu MI,
• Giovanni Abbadessa,
• Ashish Bajel

Affiliations

Anthony Selwyn Stein

1 City of Hope National Medical Center, Duarte, United States

Mojca Jongen-Lavrencic

2 Erasmus University Medical Center, Rotterdam, The Netherlands

Sylvain Garciaz

3 Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France

Gerwin A Huls

4 University Medical Center Groningen, Groningen, The Netherlands

Abhishek Maiti

5 MD Anderson Cancer Center, Houston, United States

Nicolas Boissel

6 Hôpital Saint-Louis, Paris, France

Stephane De Botton

7 Institut Gustave Roussy, Paris, France

Shaun Fleming

8 Alfred Health, Melbourne, Australia

C. Michel Zwaan

9 Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

David C. de Leeuw

10 Amsterdam University Medical Center, Amsterdam, The Netherlands

Pinkal Desai

11 Weill Cornell Medicine, New York, United States

Martha Lucia Arellano

12 Emory University, Atlanta, United States

David Avigan

13 Beth Israel Deaconess Medical Center, Boston, United States

Saskia Langemeijer

14 Radboud University Medical Center, Nijmegen, The Netherlands

Kyle Jensen

15 Sanofi, Cambridge, United States

Timothy Wagenaar

15 Sanofi, Cambridge, United States

Gu MI

15 Sanofi, Cambridge, United States

Giovanni Abbadessa

15 Sanofi, Cambridge, United States

Ashish Bajel

16 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia